Screener
Viridian Therapeutics, Inc. VRDN Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| (in thousands) / June 30, 2026 | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value |
|---|---|---|---|---|
| U.S. treasury securities | $322,051 | — | $(608) | $321,443 |
| Corporate paper and bonds | 495,648 | 7 | (554) | 495,101 |
| Total | $817,699 | $7 | $(1,162) | $816,544 |
| December 31, 2025 | ||||
| U.S. treasury securities | $223,526 | $254 | $(9) | $223,771 |
| Corporate paper and bonds | 438,297 | 241 | (39) | 438,499 |
| Total | $661,823 | $495 | $(48) | $662,270 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s cash, cash equivalents, and marketable securities?
- Viridian Therapeutics, Inc. (VRDN) reported cash, cash equivalents, and marketable securities of $816.54M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s cash, cash equivalents, and marketable securities changed year-over-year?
- Viridian Therapeutics, Inc.'s cash, cash equivalents, and marketable securities increased by 47.7% year-over-year, from $552.76M to $816.54M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s cash, cash equivalents, and marketable securities?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s cash, cash equivalents, and marketable securities has grown at a 35.4% compound annual growth rate (CAGR), from $196.87M to $662.27M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about Viridian Therapeutics, Inc.'s cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude